ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 09 December 8:00AM
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
Gmenfan Gmenfan 6 minutes ago
Duplicate please delete. Damn my old fingers!!!
Gmenfan Gmenfan 6 minutes ago
Mark Milley engaged in 1 of the purest forms of Treason known to the public

He called China’s military behind the President’s back and said he would not attack them if given the order by the President

That’s effectively a military coup

He needs to be brou
gitreal gitreal 6 minutes ago
The logic here never surprises me to be subpar.

The logic is backed by facts. It is unfortunate you choose to ignore the facts and cannot offer a reasonable rebuttal.

The XRF data is completely bogus. There is no real evidence that PGMs exist at the company mining pro
SDRC
ChannelTrader ChannelTrader 7 minutes ago
100% agree.
Mark Milley engaged in 1 of the purest forms of Treason known to the public

He called China’s military behind the President’s back and said he would not attack them if given the order by the President

That’s effectively a military coup

1hot toddy 1hot toddy 7 minutes ago
HMBL new parent co website is SMX.TECH
HMBL SMX
1hot toddy 1hot toddy 9 minutes ago
i saw website in english cant find it. here is website in brazil. ybyracapital.com.br. on trading view under ybra4 can see 40$ in brazil which is 6.56 usd. i saw somewhere on their website that they are a billion $ company.
SMX
Zardiw Zardiw 9 minutes ago
$Traded is still increasing on $RDAR, which is a good sign.......fwiw

Z
RDAR TRADED
L0tsaluck2000 L0tsaluck2000 9 minutes ago
Proto,
What would it take for you to lose confidence in Lebby or the future of LWLG?
LWLG
cjstocksup cjstocksup 10 minutes ago
Mark Milley engaged in 1 of the purest forms of Treason known to the public

He called China’s military behind the President’s back and said he would not attack them if given the order by the President

That’s effectively a military coup

He needs to be brou
Zardiw Zardiw 11 minutes ago
$HMBL - #DDAmanda Chart:

#DDAmanda XMAS Special Signup:
https://ddamanda.com/SignUpXMAS.php

Questions/Support: 760 702-2009 - Hans@DDAmanda.com

https://DDAmanda.com/Charts/DDAmandaHMBL.jpg

Z
HMBL
lighter than AIR lighter than AIR 11 minutes ago
It is good to stay positive…if we could just positively KNOW where we stand…for once.
CBRF
cjstocksup cjstocksup 12 minutes ago
https://x.com/DC_Draino/status/1865160887469810126
sokol sokol 12 minutes ago
Dr. Timo Grimmer is a prominent psychiatrist and researcher in Germany, specializing in Alzheimer's disease. He heads the Centre for Cognitive Disorders at the Technical University of Munich, focusing on early diagnosis and the use of biomarkers for neurocognitive disorders.  Grimmer has been involv
AVXL
Gmenfan Gmenfan 12 minutes ago
Trump Says He Will Act ‘On Day One’ to Pardon Jan. 6 Protesters

https://truthpress.com/news/trump-says-he-will-act-on-day-one-to-pardon-jan-6-protesters/?utm_source=truthpress.beehiiv.com&utm_medium=newsletter&utm_campaign=gop-flips-deep-blue-seat&_bhlid=9c6a48f082fb2e7b5883e4d643626b
Gmenfan Gmenfan 13 minutes ago
Trump Says He Will Act ‘On Day One’ to Pardon Jan. 6 Protesters

https://truthpress.com/news/trump-says-he-will-act-on-day-one-to-pardon-jan-6-protesters/?utm_source=truthpress.beehiiv.com&utm_medium=newsletter&utm_campaign=gop-flips-deep-blue-seat&_bhlid=9c6a48f082fb2e7b5883e4d643626b
cjstocksup cjstocksup 13 minutes ago
https://x.com/DC_Draino/status/1865160887469810126
Bright Boy Bright Boy 14 minutes ago
The loss causation exercise is multifaceted, the most important being the "multiplier effect".In Judge Stein's R&R, he agreed with all the allegations and simply asked the plaintiffs to show the formulas used to determine the loss and "How much money are they talking about" In the NWBO case the mone
NWBO
cjstocksup cjstocksup 14 minutes ago
https://x.com/DC_Draino/status/1865168478107287583
madcasper madcasper 14 minutes ago
https://x.com/Dennis_Porter_/status/1865838523741581635
CGAC
JustGoDeep JustGoDeep 14 minutes ago
Your Post Will Soon Prove Embarrassing!! Now Go Hunt!!
BIEL
cjstocksup cjstocksup 15 minutes ago
https://x.com/DC_Draino/status/1865168682764374357